Lantern Pharma Inc. (NASDAQ:LTRN), an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning ("ML") platform
The Taiwan FDA approved the amended protocol and the lead Taiwan site received IRB approval during September of 2026.
The next stage (Part 2) is a single-arm study enrolling never-smoker patients with the EGFR exon
$4 million upfront with up to an additional $4 million of potential aggregate gross proceeds upon the exercise in full of the warrants
Lantern Pharma Inc. (NASDAQ:LTRN) ("Lantern", the "Company" or
$4 million upfront with up to an additional $4 million of potential aggregate gross proceeds upon the exercise in full of the warrants
Lantern Pharma Inc. (NASDAQ:LTRN) ("Lantern", the "Company" or
Management will also discuss usage patterns, key future milestones, and an overview of the types of collaborations and partnerships under discussionInvestors, collaborators, prospective partners, and interested parties
Newly allowed claims provide LP‑284 patent protection into 2042 for the treatment of mantle cell lymphoma and double-hit lymphoma, two blood cancers with high-unmet-needs
The U.S. Patent and Trademark Office (USPTO)
Built Inside Active Clinical Programs: A New Generation of AI Co-Scientists Designed to Compress Research Timelines and Expand What Is Possible in Drug Development
Open-Medicine AI Founder & CEO Panna Sharma to
Open Medicine AI Established as a Separate Company with Executed Commercial Licenses; Progression-Free Survival Benefit Deepens in EGFR Exon 21 L858R Lung Cancer with LP-300; EMA Clears LP-184, zirdafulven, for
Webcast to be held Friday, August 14th, 9:00 a.m. ET, register for the webcast here, or at the link provided below.
Lantern Pharma Inc. (NASDAQ:LTRN), an artificial intelligence ("AI") company developing
The Open-Medicine AI multi-agentic co-scientist platform represents the strategic evolution of withZeta.ai and is expanding into additional disease areas and modalities.
The creation of the new entity, signed
Investigator-initiated European study will evaluate a distinctive dual-biomarker precision-oncology strategy — PTGR1 overexpression combined with tumor-specific Nucleotide Excision Repair — in patients with advanced
Allowed patent claims cover the use of a three-gene expression signature — PTGR1, PTPN14, and ASPH — to identify patients for treatment with LP-184 (Zirdafulven)
In a completed 63-patient Phase 1a trial, LP-184
First previewed in the company’s May roadmap, the new withZeta.ai module now enters early access with leading bioinformatics teams and Lantern collaborators — autonomously designing experiments, building rigorous
Exon 21 L858R NSCLC Mutated Patients Treated Through Up to Six Cycles Reached 8.9-Month Median PFS; Durable Responses Beyond Two Years; and a Consistently Clean Safety Profile.
PFS benefit deepens with treatment
The FDA raised no objections to Lantern's key proposed protocol amendments to the HARMONIC™ clinical trial.
Amendments include: (1) enriching enrollment for patients with EGFR exon 21 L858R mutations; (2)
